Navigation Links
Bioamber announces world's first bio-based succinic acid plant: helping to reduce dependence on fossil fuels
Date:12/16/2008

PRINCETON, NJ, Dec. 16 /PRNewswire/ - DNP Green Technology and ARD are pleased to announce that their Bioamber joint venture has obtained the necessary permits and begun construction of the world's first production plant for bio-based succinic acid. The succinic acid plant will have an annual production capacity of 2,000 metric tons and will be integrated into an existing bio-refinery located in Pomacle, France. The plant, which is being financed by ARD at a cost of US $27m, will begin production in the fall of 2009. This technological milestone represents a significant step forward for renewable, bio-based chemistry and it will help reduce the world's dependence on fossil fuels.

Bioamber's production of bio-based succinic acid can use various renewable feedstocks such as wheat, corn, sugar cane, rice, lingo-cellulose and glycerin. Succinic acid and succinate esters can be used as building blocks in a multitude of markets including biopolymers, plastics, polyesters, resins, runway deicers, non-toxic solvents and renewable fuels (as a diesel additive).

The plant demonstrates the technological breakthrough of the US Department of Energy's proprietary E. coli bacterium, which is under exclusive license to DNP Green Technology and has been optimized by Bioamber. Bioamber's fermentation technology is cost competitive with the petrochemical processes. Bioamber's revolutionary platform also offers an important environmental advantage: it consumes CO(2), as opposed to equivalent petrochemical processes that emit greenhouse gases.

"This plant will showcase our technology at a commercial scale and prove our cost competitiveness with petrochemical feedstocks", said Patrick Piot, Bioamber's General Manager. Jean Francois Huc, President of DNP Green Technology, added: "This plant clearly demonstrates that Bioamber is the world leader in bio-based succinic acid and it will assist us in our ongoing work with a variety of industry partners seeking renewable, non-petroleum feedstocks for chemical and fuel markets."

DNP Green Technology and ARD are excited about this milestone and expect Bioamber to make important announcements in the coming months on new strategic partnerships, contract sales of bio-based succinic acid and the out-licensing of the technology platform to third parties through turn-key packages.

About ARD

ARD (Agro-Industrie Recherches et Developpements) is the R&D centre of the Champagne Ardenne agricultural cooperativesthat grow cereals, sugar, and alfalfa. Representative of the global-scale competitive cluster of agricultural industries and resources, ARD adds value to and finds new outlets for agricultural crops and develops innovative and competitive products that use the renewable carbon in plants after processing in a bio-refinery. Along with its affiliate SOLIANCE, which specializes in the production and commercialization of active ingredients for the cosmetics industry, and WHEATOLEO, a joint venture with OLEON in the market for surfactants of vegetable origin, ARD has 25 years of experience in the fractionation of plants, green chemistry, and white biotechnology. ARD and its affiliates have approximately 130 employees.

For more information, please visit www.a-r-d.fr

About DNP Green Technology

DNP Green Technology is a private US company dedicated to the development of innovative technologies that use renewable biomass to produce green building blocks for the chemical industry that are cost competitive with fossil fuels. Thanks to its numerous scientific and business partnerships, DNP Green Technology has succeeded in building an extensive portfolio of patents and expertise in the production and purification of bio-based succinic acid and derivative products, as well as their use in various applications. DNP Green Technology has offices in Princeton, N.J., and Montreal, Canada.

For more information, please visit www.dnpgreen.com

About Bioamber

Bioamber is a white biotechnology company dedicated to the production of bio-based succinic acid and derivatives. Bioamber is a joint venture established between DNP Green Technology and ARD.

For more information, please visit www.bio-amber.com


'/>"/>
SOURCE DNP GREEN TECH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OmegaGenesis Announces Angiogenesis Application Collaboration
2. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
3. Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury
4. Osteotech Announces Stock Repurchase Program
5. Martek Announces Fourth Quarter and FY 2008 Financial Results
6. Helix BioPharma Announces Q1 2009 Financial Results
7. Neogen Announces New Share Repurchase Program
8. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
9. Oridion Announces Significant Medical Research to be Presented at AARC Congress
10. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
11. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... Clinical Supplies Management ... acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). TCS ... drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across Europe. ...
(Date:12/6/2016)... 2016  SRI International has been awarded a ... National Institutes of Health,s National Institute of Allergy ... (NIAID-DAIDS) to support the manufacturing and characterization of ... Under the seven-year contract, SRI will provide a ... candidate HIV-prevention products that emerge from investigator-initiated studies ...
(Date:12/5/2016)... Bermuda , Dec. 5, 2016 Axovant ... clinical-stage biopharmaceutical company focused on the treatment of dementia, ... intepirdine for the treatment of Alzheimer,s disease will be ... (CTAD) Meeting on Friday, December 9, 2016 in ... will show results of both simple and complex measures ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of AxioMed’s ... disc production, company President, Jake Lubinski will be traveling to Germany on December ... in Cologne and Karlsruhe to discuss the benefits of a viscoelastic total disc ...
Breaking Biology Technology:
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... LONDON , Nov. 17, 2016 Global Market ... and Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market ... Geographical analysis for Private Biobanks shows the highest Compounded Annual ... Asia-Pacific region during the analysis period 2014-2020. ... a CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):